Preventing cancer metastasis has long centered on stopping primary tumor spread, but circulating tumor cells floating through the bloodstream represent an overlooked vulnerability. These cellular hitchhikers seed distant organs, making their elimination a critical but technically challenging therapeutic target that could transform cancer outcomes.
This investigation demonstrates that riboflavin combined with blue light phototherapy selectively destroys colorectal cancer cells in circulation while leaving healthy blood components intact. The treatment triggers PANoptosis—a comprehensive cell death program simultaneously activating pyroptosis, apoptosis, necroptosis, and ferroptosis pathways. Mitochondrial reactive oxygen species emerge as the central killing mechanism, with riboflavin accumulating preferentially in cancer cell mitochondria before blue light activation creates lethal oxidative damage.
The precision of this approach addresses a fundamental challenge in cancer therapeutics: how to eliminate malignant cells without collateral damage to essential blood functions. Unlike systemic chemotherapy, which broadly suppresses immune cells and disrupts coagulation, this photochemical strategy exploits cancer cells' altered metabolism to concentrate riboflavin in their mitochondria. The resulting oxidative burst overwhelms their antioxidant defenses while sparing normal blood cells that process riboflavin differently. This selectivity could enable treatment of patients with active circulation metastases—a population currently facing limited options. However, the transition from laboratory models to clinical application requires validating the approach in human blood samples and determining optimal dosing protocols. The multiple cell death pathways activated suggest cancer cells cannot easily develop resistance, potentially offering durable protection against metastatic seeding.